{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:52:04Z","timestamp":1789685524442,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40744-025-00793-3","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:18:03Z","timestamp":1759249083000},"page":"1103-1123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03675308","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03671148","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4827","authenticated-orcid":false,"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Keiserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5513-7572","authenticated-orcid":false,"given":"Angela","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-8511","authenticated-orcid":false,"given":"Douglas","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Biljan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-7757","authenticated-orcid":false,"given":"Tshepiso","family":"Madihlaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8632-1396","authenticated-orcid":false,"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-0879","authenticated-orcid":false,"given":"Michael","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-7516","authenticated-orcid":false,"given":"Lila","family":"Glotfelty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"10","key":"793_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"4","key":"793_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"793_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.20162","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Cook R, Lee K, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res. 2010;62(7):970\u20136.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"793_CR4","first-page":"187","volume":"10","author":"MJ Bergman","year":"2023","unstructured":"Bergman MJ, Zueger P, Patel J, Saffore CD, Topuria I, Cavanaugh C, et al. Clinical and economic benefit of achieving disease control in psoriatic arthritis and ankylosing spondylitis: a retrospective analysis from the OM1 Registry. Rheumatol Ther. 2023;10(1):187\u201399.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"793_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41927-018-0030-y","volume":"2","author":"LC Coates","year":"2018","unstructured":"Coates LC, Orbai AM, Morita A, Benichou O, Kerr L, Adams DH, et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients\u2019 health-related quality of life and productivity. BMC Rheumatol. 2018;2(1):24.","journal-title":"BMC Rheumatol"},{"issue":"8","key":"793_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016619","volume":"7","author":"P Rahman","year":"2017","unstructured":"Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, et al. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open. 2017;7(8): e016619.","journal-title":"BMJ Open"},{"issue":"1","key":"793_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4081\/reumatismo.2020.1266","volume":"72","author":"FM Perrotta","year":"2020","unstructured":"Perrotta FM, Sedie AD, Scriffignano S, Volpe P, Cordisco E, Milano N, et al. Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12\/23 and IL-17 inhibitors. A multicenter prospective study. Reumatismo. 2020;72(1):52\u20139.","journal-title":"Reumatismo"},{"issue":"6","key":"793_CR8","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/ar4413","volume":"15","author":"MB \u0106alasan","year":"2013","unstructured":"\u0106alasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R217.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"793_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7(4):778\u201391.","journal-title":"MAbs"},{"issue":"12","key":"793_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE. 2021;16(12): e0260954.","journal-title":"PLoS ONE"},{"issue":"1","key":"793_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1964420","volume":"13","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021;13(1): 1964420.","journal-title":"MAbs"},{"issue":"2","key":"793_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"793_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, den Bosch FV, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"793_CR14","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1111\/jdv.17931","volume":"36","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Soliman AM, Papp K, Merola JF, Barcomb L, Wang Z, et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol. 2022;36(5):e389\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"793_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","volume":"62","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology. 2022;62(6):2113\u201321.","journal-title":"Rheumatology"},{"issue":"6","key":"793_CR16","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","volume":"62","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, den Bosch FV, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatol (Oxf, Engl). 2022;62(6):2122\u20139.","journal-title":"Rheumatol (Oxf, Engl)"},{"issue":"3","key":"793_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","volume":"11","author":"LE Kristensen","year":"2024","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Carter K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the phase 3 KEEPsAKE 1 randomized clinical trial. Rheumatol Ther. 2024;11(3):617\u201332.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"793_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s40744-024-00657-2","volume":"11","author":"A \u00d6st\u00f6r","year":"2024","unstructured":"\u00d6st\u00f6r A, den Bosch FV, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE 2 randomized clinical trial. Rheumatol Ther. 2024;11(3):633\u201348.","journal-title":"Rheumatol Ther."},{"issue":"2","key":"793_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000588","volume":"3","author":"K Shah","year":"2017","unstructured":"Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2): e000588.","journal-title":"RMD Open"},{"issue":"2","key":"793_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","volume":"79","author":"X Li","year":"2020","unstructured":"Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79(2):285\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"793_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","volume":"22","author":"KW Hagberg","year":"2016","unstructured":"Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS. Rates of cancers and opportunistic infections in patients with Psoriatic arthritis compared with patients without psoriatic arthritis. JCR J Clin Rheumatol. 2016;22(5):241\u20137.","journal-title":"JCR J Clin Rheumatol"},{"issue":"9","key":"793_CR22","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328\u201337.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"793_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2013-205148","volume":"75","author":"D Zisman","year":"2016","unstructured":"Zisman D, Bitterman H, Shalom G, Feldhamer I, Comanesther D, Batat E, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016;75(1):131.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"793_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","volume":"21","author":"L Li","year":"2015","unstructured":"Li L, Hagberg KW, Peng M, Shah K, Paris M, Jick S. Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis. JCR J Clin Rheumatol. 2015;21(8):405\u201310.","journal-title":"JCR J Clin Rheumatol"},{"issue":"1","key":"793_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","volume":"22","author":"B Combe","year":"2020","unstructured":"Combe B, Rahman P, Kameda H, Ca\u00f1ete JD, Gallo G, Agada N, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"793_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"793_CR27","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","volume":"61","author":"LP Vegas","year":"2021","unstructured":"Vegas LP, Corvoisier PL, Penso L, Paul M, Sbidian E, Claudepierre P. Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology. 2021;61(4):1589\u201399.","journal-title":"Rheumatology"},{"issue":"1","key":"793_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2024","unstructured":"Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47(1):39\u201357.","journal-title":"Drug Saf"},{"issue":"24","key":"793_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247653","volume":"12","author":"DH Kang","year":"2023","unstructured":"Kang DH, Lew BL, Kwon SH. Incidence of new-onset inflammatory bowel disease, oral and gastrointestinal candidiasis, herpes zoster, pulmonary tuberculosis, and major cardiovascular events in patients with moderate-to-severe psoriasis exposed to biologics. J Clin Med. 2023;12(24): 7653.","journal-title":"J Clin Med"},{"issue":"4","key":"793_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis. JAMA Dermatol. 2020;156(4):421\u20139.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"793_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, Gratac\u00f3s J, Turkiewicz A, Hall S, Dokoupilova E, Combe B, et al. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-year follow-up (SPIRIT-P2). Rheumatol Ther. 2021;8(1):199\u2013217.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"793_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40744-024-00713-x","volume":"11","author":"P Mease","year":"2024","unstructured":"Mease P, Korotaeva T, Shesternya P, Kokhan M, Rukavitsyn A, Vasilchenkov D, et al. Guselkumab in biologic-na\u00efve patients with active psoriatic arthritis in Russia: a post hoc analysis of the DISCOVER-1 and \u2013 2 randomized clinical trials. Rheumatol Ther. 2024;11(6):1551\u201367.","journal-title":"Rheumatol Ther."},{"issue":"10","key":"793_CR33","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","volume":"59","author":"V Chandran","year":"2020","unstructured":"Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, et al. Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology. 2020;59(10):2774\u201384.","journal-title":"Rheumatology"},{"issue":"3","key":"793_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"793_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acr2.11097","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18\u201325.","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"793_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year follow-up from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res. 2017;69(3):347\u201355.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"793_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.semarthrit.2016.07.006","volume":"46","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Landew\u00e9 R, Smolen J. Review of head-to-head study designs in rheumatoid arthritis. Semin Arthritis Rheum. 2016;46(3):279\u201385.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"793_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","volume":"44","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, Wit M, Duffin KC, Campbell W, Chau J, Coates LC, et al. Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J Rheumatol. 2017;44(5):697\u2013700.","journal-title":"J Rheumatol"},{"issue":"6","key":"793_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/17407745241244788","volume":"21","author":"KM Higgins","year":"2024","unstructured":"Higgins KM, Levin G, Busch R. Considerations for open-label randomized clinical trials: design, conduct, and analysis. Clin Trials. 2024;21(6):681\u20138.","journal-title":"Clin Trials"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00793-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:46:43Z","timestamp":1763732803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00793-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00793-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew \u00d6st\u00f6r has received speaker or consulting fees and\/or research grants from AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. Filip Van den Bosch has received speaker and\/or consulting fees from AbbVie, Alfasigma, Celgene by Amgen, Fresenius Kabi, Galapagos, Janssen, Lilly, Novartis, and UCB. Kim Papp has received honoraria and\/or grants from, is a consultant, investigator, or a scientific officer for AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite BioPharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DICE Therapeutics, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. Mauro Keiserman has served as a speaker for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; was a consultant for AbbVie, Biogen, Bristol Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Sanofi; and receives grant\/research support from AbbVie, Biogen, Bristol Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Sanofi. Ricardo Blanco has received grants or research support from AbbVie, Merck, and Roche. He has received consultation fees or honoraria for serving as a speaker for AbbVie, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, and Roche. Angela Crowley has received research funds, honoraria, or fees for serving as a consultant or speaker from AbbVie, Acelyrin, Amgen, AstraZeneca, GlaxoSmithKline, Kiowa-Kirin, Janssen, Lilly, Novartis, SetPoint Medical, and UCB. Douglas White has received honoraria or fees for serving on advisory boards or as a speaker or consultant from AbbVie. Alan Kivitz has received consulting fees from Frescenius Kabi, Genzyme, Gilead, GlaxoSmithKline, Gr\u00fcnenthal, Horizon, Janssen, Pfizer, Selecta, SynAct, and Takeda; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB; has served on boards or advisory boards for Biopartners, ChemoCentryx, Horizon, Janssen, Novartis, Princeton, and UCB; and has stock or stock options in Amgen, GlaxoSmithKline, Gilead, Novartis, and Pfizer. Doug Ashley, Ana Biljan, Kyle Carter, Michael Chen, Fang Liu, Tshepiso Madihlaba, Ahmed M. Soliman, and Lila Glotfelty are employees of AbbVie Inc., and may own stock\/stock options and patents in the company. We thank the participants of the study. The authors would like to thank all the trial investigators for their contribution and the patients who participated in this trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Independent Ethics Committee or Institutional Review Board at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The coordinating investigators for KEEPsAKE 1 (Lars Erik Kristensen of the Parker Institute, Frederiksberg, Denmark) and KEEPsAKE 2 (Alan Kivitz of the Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA) received approval from the Danish Health Research Ethics Committee and the Quorum International Review Board, respectively. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent before screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}